Introduction
Antimicrobial resistance is a major public health concern and is identified by the WHO as one of the three greatest threats to human health. 1 The development of resistance is related to excessive use of antimicrobial drugs. In this context, antibiotic stewardship programmes (SPs) have been proposed as an opportunity to contain antimicrobial resistance. 2, 3 They are supported by guidelines published by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America. 4, 5 The benefits of antibiotic SP are well-known and include improved patient outcomes, reduction of adverse events including Clostridium difficile infections, reduction in antibiotic resistance and optimization of resource consumption. 4, 5 Resistance concerns are not limited to antibacterials as antifungal resistance is also a significant and emerging threat, mainly to azoles for Candida and Aspergillus: resistance rates were reported V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. between 11.9% and 14% for Candida glabrata and over 2.3% for Aspergillus fumigatus, with higher rates in some regions reflecting disparities in microbiological procedures to detect resistance. 6 As demonstrated for antibiotics, inappropriate antifungal use contributes to an increase in resistance, mortality, morbidity and costs. 7 While antibiotic SPs are widely implemented, 8 few implementations of antifungal SPs have been reported in the literature.
Antifungal SP is defined as an optimal use of antifungals through careful selection of agents based on patient profile, target organism, toxicity, cost, as well as the likelihood of emergence and spread of antifungal resistance. 9 Antifungal SP initiatives aim to improve outcomes, avoid adverse drug-related effects, reduce emergence of resistance, more rapidly diagnose the fungal agent and control costs. 7 While antifungal SP implementation has been recently described in reviews of the literature, 7, [9] [10] [11] [12] [13] [14] [15] there is yet to be an overview of interventions and their impact on performance measures. The objective of this study was therefore to analyse systematically the antifungal SP studies to describe interventions and their impact on performance measures.
Methods

Eligibility criteria
Studies that described an antifungal SP and included an intervention and a performance measure were eligible; reviews, non-interventional studies, as well as those not written in English, were excluded.
Search and information sources
MEDLINE was searched using the term 'antifungal stewardship ' 
Study selection
After screening the 97 records for duplicates, abstracts were uploaded in MEDLINE to assess eligibility of articles. If the abstract was not informative to assess eligibility, full texts were retrieved from the university library. To increase the completeness of the search, a snowballing approach was used: references of eligible articles and pertinent reviews were scanned. 16 To resolve disagreement for inclusion, full-text articles were read in full independently by two investigators (A. L. B. and G. L.) leading to a consensus after discussion.
Data extraction
The full texts of the included articles were retrieved from the university library. Information about context, objectives, number of patients or reviewed prescriptions, interventions and performance measures [antifungal use, adherence to therapeutic advice, quality of care, mortality, incidence of invasive fungal infection (IFI)] was extracted after each included full-text article was read in full. To ensure reproducibility and completeness of data extraction, an Excel spreadsheet (Microsoft Corp., Redmond, WA, USA) compiling all variables to be extracted was used. Data extraction was double-checked by A. L. B. and G. L. Disagreements over data extraction were resolved by discussion. Data were centrally checked by an independent operator for completeness, plausibility and integrity before synthesis.
Synthesis of results and summary measures
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) check-list 2009 was used as a methodological support of the systematic review.
17
A narrative synthesis approach was used to summarize data extracted from full-text articles.
Results
A total of 97 records were identified; one record 18 was identified using a snowballing approach. Among the 97 records, 64 did not describe an antifungal SP and were excluded. Among the 33 full texts assessed, 16 were antifungal SP reviews, two were noninterventional studies and one was not written in English; these articles were excluded. Thus, 14 studies were eligible for systematic review (Figure 1) .
Half of the studies were published in 2014 or later. The first study describing an antifungal SP with an intervention was published in 2009; its objective was to evaluate the impact of implementing practice guidelines for antifungal therapy in a surgical intensive care unit on the use and cost of antifungals.
18 Three (of 14) studies [19] [20] [21] were specifically dedicated to candidaemia, and 1 (of 14) 22 also included data on antibiotic SP. Nine of 14 studies were conducted in tertiary care hospitals, and five in university hospitals (Table 1) . To collect information about the initiation of antifungal treatment, most studies (10 of 12) used pharmacy data, one study used microbiology data 23 and one study was based on regular visits to a haematology unit 24 ( Table 1 ). The objective of the studies was to evaluate the impact on antifungal use of a review of prescription (12 of 14) or implementation of practice guidelines (2 of 14). The study period ranged from 6 months to 13 years (Table 1) ; the median study duration was 1 year. Five studies incorporated a non-interventional period considered as a control period that doubles the time of the study (Table 1) . [18] [19] [20] 23, 25 Among the 12 studies that included a review of prescriptions, only five reported an antifungal stewardship team composed of all the recommended members [i.e. an infectious disease (ID) specialist, a clinical pharmacist and a clinical microbiologist]; 20, 23, [25] [26] [27] four lacked a clinical microbiologist, 19, 21, 22, 28 one lacked an ID specialist, 29 one lacked an ID specialist and a clinical microbiologist, 24 and one lacked a clinical microbiologist and a clinical pharmacist. 24 All studies (n " 12) included in their review of prescriptions echinocandins, liposomal or lipid complex amphotericin B, voriconazole and posaconazole. Two studies also included fluconazole 18, 20 and two studies included fluconazole and itraconazole 18, 20 (Table 1) . A mean of 258 patients (range 42-1106) were included in the studies (n " 9) and a mean of 526 (range 280-662) prescriptions were reviewed (n " 3); the number of patients and prescriptions were not reported for two studies. 18, 22 Among studies in which all core members were represented in the antifungal stewardship team (n " 5), a mean of 577 patients (range 453-1106) were reviewed, and in studies in which the team lacked at least one member (n " 7), a mean of 137 patients (range 78-192) were reviewed.
Among the 14 articles included in the present review, the most frequent intervention was the formulation of recommendations to change treatment (12 of 14; Table 2 ). In the majority of studies (10 of 14), the recommendations were formulated directly to Systematic review the clinician in charge of the patient, and in the remaining studies (2 of 14), the recommendations were included in an electronic medical record. 21, 27 In two (of 14) studies, the only intervention was the implementation of practice guidelines. 18, 30 A minimum of three performance measures were collected in half of the studies including a review of prescription (6 of 12) . Among the studies with a complete stewardship team (n " 5), more than three performance measures were collected, and in studies with an incomplete stewardship team, one (1 of 7) or two (5 of 7) measures were collected ( Table 2) .
The most frequent performance measure collected was antifungal consumption (10 of 14): reduction in consumption ranged from 11.8% to 71%, and reduction in DDD ranged from 17% to 52% (3 of 14) . A reduction of 2 days of therapy was reported from one study. 31 A reduction of antifungal cost was found in half of the studies (7 of 14), and cost containment was reported in one study. 23 A decrease of 50% in antifungal use and .50% in antifungal cost was reported in one of the two studies based on implementation of treatment guidelines only (Table 2) . 18 Adherence to therapeutic advice was evaluated in four of the 12 studies that included a review of prescription and ranged from 40% to 88%. Among these, one study used an electronic medical record and found 40% adherence. 27 The impact of antifungal SP in terms of mortality was evaluated in 4 of 14 studies, and in terms of IFI incidence in 3 of 14 studies. From these studies, no impact on mortality or on IFI incidence was observed. Conversely, one of the four studies that investigated quality of care found an improvement in this measure. Other performance measures were reported, e.g. the proportion of appropriate prescriptions 20 and time to effective therapy, 23 which were improved by antifungal SPs. For studies focusing on candidaemia, [19] [20] [21] incidences of Candida krusei, C. glabrata, and Candida albicans were evaluated, as was the time to clearance of candidaemia and rate of ophthalmological examinations. Antifungal SPs had a positive impact on the rate of resistant Candida 20 and ophthalmological examinations 19 ( Table 2) .
Discussion
Antifungal stewardship is a recent matter of debate, which is illustrated by the publication date of the included studies, the majority Full-text articles assessed for eligibility (n =33)
Full-text articles excluded, with reasons (n =19)
Reviews (n =16) Non-interventional studies (n =2) Study not written in English (n =1) Studies included in qualitative synthesis (n =14)
Records identified through database searching (n =96) Figure 1 . PRISMA flow diagram mapping out the number of records identified, included and excluded, and the reasons for exclusions.
Systematic review Systematic review of which were published from 2014. It was found from this review that antifungal SPs were implemented in tertiary care hospitals or university hospitals, which can be explained by the frequent use of these drugs in critically ill patients admitted to such healthcare structures, as well as the availability of human resources and facilities required to implement antifungal SP. 8 The role of the multidisciplinary team to ensure optimal management of IFI is unquestionable. 32 It should include ID specialists, a clinical pharmacist and a clinical microbiologist. 7 However, among the 12 articles including a review of prescription, only five articles reported a complete antifungal stewardship team. An information system specialist, infection control professional and hospital epidemiologist are also included in the antibiotic SP team according to IDSA guidelines. 5 It is of note that none of the included studies had a stewardship team that included such healthcare professionals and the recommendations for antifungal SP do not stipulate the inclusion of these. Interestingly, among the studies included herein, the number of prescriptions reviewed and performance measures collected were greater if the antifungal stewardship team was complete, which suggests more extensive investigations are performed when the required human resources are allocated to the SP. This is in accordance with a review describing Australasian resources and activities for antimicrobial SP from which it appears that a lack of personnel involved in SP was a barrier to successful antimicrobial SP. 33 Furthermore, it has been suggested that the absence of a pharmacist is associated with an increased rate of inappropriate antimicrobial use and an increased duration of treatment. 34 However, it is not possible to comment further on this aspect from the studies included herein; only one study did not include a pharmacist, and furthermore did not report on these parameters. 24 The most frequent intervention was the formulation of recommendations to change treatment. According to Muñoz et al., 12 formulation of therapeutic advice is part of the persuasive interventions that require more time and effort, but which have long-term acceptance. In one of the two studies only based on implementation of guidelines, 35 authors obtained an impact on antifungal consumption and cost, but it is not indicated if the action was sustainable or not. An interesting future development in antifungal SP may be the use of rapid diagnostic tests, including Candida molecular diagnostic techniques, which have been proposed by Goff et al. 35 and Denning et al. 36 to optimize antimicrobial selection, control antimicrobial resistance and improve clinical outcome; to our knowledge, the impact of this intervention through an antifungal SP has yet to be evaluated.
JAC
Muñoz et al. 12 also noted that indicators are mandatory for antifungal SP. Two types of indicators are required: process measures, and outcome measures. 10 This has been further detailed by Ananda-Rajah et al.
11 who published a detailed list of performance measures for antifungal SP: process measures include antifungal drug consumption, minimum standards of prescribing, therapeutic streamlining, timeliness and completeness of diagnostic investigations when IFI is suspected, and concordance of prescribing with institutional guidelines; outcome measures include IFI incidence in targeted groups and antifungal drug expenditure. Moreover, Ananda-Rajah et al.
11 created a specific performance measure for antifungal SP named 'structural measures' that include an antifungal drug policy and locally adapted practice guidelines. Conversely, bundle of care indicators in patients with candidaemia were Ramos et al. 15 Interestingly, all types of performance measures were collected in the 14 studies included in the present review. It has to be noted that only a few studies evaluated the impact of antifungal SP on IFI incidence and mortality, as a good indication of quality of care: this is in accordance with IDSA guidelines that consider measurement of antibiotic SP impact on outcome more challenging than measuring antibiotic use or guideline compliance. 5 The most frequent process measure was antifungal consumption using DDD. According to IDSA guidelines, days of therapy are preferred because they are not impacted by dose adjustments and can be used in paediatrics when weight-based dosing is required. However, DDDs remain an alternative if patient-level antimicrobial use data cannot be obtained. 5 The second most frequent process measure collected was the agreement of prescribing with treatment guidelines. Near perfect agreement was obtained in an antifungal SP that was only based on implementation of modified guidelines. 30 The level of adherence to therapeutic advice was also evaluated in four studies and it is of note that the lowest adherence was obtained using an electronic medical record to formulate therapeutic advice; 27 direct interactions with the clinicians in charge of the patient seem more efficient to obtain better compliance. 28 The most frequent outcome measure (reported in half of included studies) was antifungal expenditure; although cost is considered to be a secondary goal for antimicrobial stewardship, cost saving is one way to justify continued administrative support for antimicrobial SP activities. 5 All studies included herein focused on high-cost antifungals and only a few also included fluconazole and itraconazole. 18, 20, 22, 23 It could, however, be of interest to study fluconazole resistance, as the potential of fluconazole to induce resistance in Candida is high. However, it has to be noted that resistance as an indicator of SP is considered by IDSA guidelines to be a very complex metric because resistance development and spread is multifactorial. 5 In antifungal SP, only two studies evaluated Candida resistance; 20, 26 one reported a lower level of resistant Candida after an antifungal SP implementation. 20 Length of hospitalization, days of hospitalization avoided, as well as parenteral therapy and days of central venous access avoided, are preferred metrics for antibiotic SP because it is a consequence of therapeutic streamlining. 5 From the 14 studies, only two related to candidaemia evaluated the length of hospitalization that remained unchanged despite antifungal SP. Surprisingly, among the outcome measures reported in the included studies, occurrence of adverse events was not used.
The main limitation of this systematic review is the low number of research papers on the topic. Incomplete retrieval is possible for papers outside MEDLINE.
Conclusions
All antifungal SPs included in this systematic review had an impact on antifungal prescription, in particular on antifungal consumption and antifungal expenditure. The multidisciplinary team, as well as face-to-face discussion about antifungal prescription, appear to be cornerstones of antifungal SP. A future direction could be the development of guidelines for antifungal SP implementation, as is currently the case for antibiotics.
